American Century Companies Inc. Acquires 6,553 Shares of REGENXBIO Inc. $RGNX

American Century Companies Inc. grew its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 6.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 101,579 shares of the biotechnology company’s stock after buying an additional 6,553 shares during the period. American Century Companies Inc. owned 0.20% of REGENXBIO worth $726,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of RGNX. Raymond James Financial Inc. bought a new stake in shares of REGENXBIO during the 4th quarter valued at $568,000. Dimensional Fund Advisors LP boosted its holdings in shares of REGENXBIO by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock valued at $9,054,000 after buying an additional 21,234 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of REGENXBIO by 442.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 10,714 shares in the last quarter. Stifel Financial Corp boosted its holdings in shares of REGENXBIO by 26.5% during the 4th quarter. Stifel Financial Corp now owns 188,844 shares of the biotechnology company’s stock valued at $1,460,000 after buying an additional 39,564 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,982 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $9.42 on Friday. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $13.48. The business has a 50-day simple moving average of $8.63 and a two-hundred day simple moving average of $8.16. The firm has a market cap of $475.80 million, a price-to-earnings ratio of -2.74 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million during the quarter, compared to analysts’ expectations of $40.87 million. As a group, research analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a report on Tuesday, August 19th. Royal Bank Of Canada dropped their price target on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Friday, August 8th. Finally, Barclays dropped their price target on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.